Internal Medicine, Hematology & Oncology · New York, NY
NPI
1215467097
Since 2017
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
160 E 53rd St
New York, NY, 10022
Phone (212) 639-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$58K
698 services
Medicare patients, 2024
150
Average age 77
Drug cost, 2024
$2.1M
344 prescriptions
Company payments, 2025
$2,581
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James W Smithy was code 99213 (office e&m - established), 279 times for 85 patients. In total James W Smithy billed 698 services in 13 codes, and Medicare paid $58K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-04-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 279 | 85 | $61.25 | $17K |
| 99214 Office E&M - Established | Office | 195 | 82 | $91.47 | $18K |
| 99233 Hospital E&M - Subsequent | Facility | 63 | 14 | $103.04 | $6,491 |
| 99205 Office E&M - New | Office | 55 | 55 | $160.24 | $8,813 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 49 | 27 | $14.30 | $701 |
| 99215 Office E&M - Established | Office | 34 | 28 | $135.06 | $4,592 |
By year: 2022 $7,397 for 117 services; 2023 $12K for 155 services; 2024 $58K for 698 services.
Medicare prescription drug claims, 2024
In 2024, the drug James W Smithy prescribed most often to Medicare patients was Tafinlar (Dabrafenib Mesylate), with 44 prescriptions and refills. In total James W Smithy wrote 344 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tafinlar Dabrafenib Mesylate | 44 | 44 | Under 11 | $588K |
| Mekinist Trametinib Dimethyl Sulfoxide | 35 | 46 | Under 11 | $637K |
| Prednisone Generic | 28 | 28 | 12 | $168 |
| Mektovi Binimetinib | 28 | 28 | Under 11 | $391K |
| Levothyroxine Sodium Generic | 28 | 44 | Under 11 | $326 |
| Braftovi Encorafenib | 28 | 28 | Under 11 | $398K |
| Trazodone Hcl Generic | 13 | 17 | Under 11 | $67.39 |
| Triamcinolone Acetonide Generic | 13 | 14 | Under 11 | $180 |
Brand drugs: 163 claims; generic drugs: 181 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James W Smithy $2,581 ($2,581 in general payments such as food, travel and fees) from 3 companies. The largest payer was Daiichi Sankyo Inc. with $1,626.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.